Infinite Epigenetics Acquires Tally Health, Consolidating Epigenetic Longevity Market
The acquisition of Tally Health by Infinite Epigenetics creates a dominant force in epigenetic testing, integrating research with a consumer-facing brand and supplement line.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 29 April 2026
Infinite Epigenetics has acquired Tally Health, merging their respective epigenetic testing and analytics platforms with Tally Health's established consumer-facing brand and supplement portfolio. This transaction unites the largest privately held DNA methylation dataset, providing an unparalleled resource for validating interventions including nutrition and dietary supplements across diverse demographics. The consolidated data improves scientific rigour for product development and claims substantiation within the burgeoning longevity sector.
Tally Health will maintain its brand identity and operational autonomy post-acquisition. However, it gains direct access to Infinite Epigenetics’ advanced laboratory infrastructure and expanded data reservoirs. This integration facilitates a more data-driven approach to product development, enabling continuous iterative formulation based on real-world epigenetic response data. The combined platform aims to directly link epigenetic testing outcomes with downstream interventions, continuously assessing their impact on biological ageing markers.
This strategic consolidation represents a significant shift in the epigenetic market, underscoring a move towards vertical integration where data generation, analysis, and consumer-facing product delivery are housed under one entity. For supplement manufacturers, this means a higher bar for evidence-based product development and a potential acceleration of ingredient validation for efficacy in biological ageing. Brands without similar access to robust, proprietary datasets may struggle to compete effectively on claims and innovation.
What this means for United Kingdom
UK supplement brand owners specialising in longevity and anti-ageing products face immediate strategic implications. The combined Infinite Epigenetics/Tally Health entity will set a new industry benchmark for validated epigenetic claims, potentially pressuring smaller UK brands to invest significantly more in efficacy studies. Procurement leads should anticipate a shift towards ingredients with stronger, epigenetically validated mechanisms. Compliance teams must prepare for increased regulatory scrutiny on biological ageing claims, with the MHRA and FSA likely reviewing evolving evidence standards. This presents an opportunity for UK manufacturers with strong R&D capabilities to partner or compete on advanced biomarker-driven formulations, securing market share in a rapidly professionalising segment.
The acquisition also suggests a future where product development cycles are dramatically shortened, driven by continuous feedback from large-scale epigenetic testing. This iterative design philosophy will favour manufacturers who can rapidly reformulate and adapt to emerging data, rather than relying on traditional, slower R&D pipelines. The ability to demonstrate a measurable impact on epigenetic markers will become a key differentiator in a crowded market.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.